Bayer’s finerenone hits targets in diabetes/kidney disease trial
The drug hit primary and secondary goals of the Phase III FIDELIO-DKD renal outcomes study
Read More
Tag: diabetes 2
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
